ANRS 0029s SimpPrEP
A randomised, controlled trial to evaluate the efficacy, acceptability and safety of Event-driven HIV PrEP using TAF/FTC among men who have sex with men (MSM) in Thailand and France.
Last updated on 27 February 2024
Primary objective
To assess the efficacy of emtricitabine 200 mg + tenofovir alafenamide 25 mg (F/TAF), taken 2 to 24 hours before sexual intercourse followed by a second dose 24 hours after the first intake, in reducing the risk of HIV acquisition in MSM relative to the background HIV incidence rate.
Theme
VIH
Population
Adults
Status
Ongoing
Samples
Plasma, Serum
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr